If you run a head to head studies involving DuAVR and S3 , after the initial 2 results from DuAVR , you would have to call off the studies for ethical reasons. So knowing the haemodynamics of DuAVR in VIV, it would be hard for clinicians to recommend anything other than DuAVR for VIV.
Ann: Exceptional Results in Second Valve-in-Valve Case, page-42
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $326.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $169.0K | 9.937K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1460 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.10 | 1 | 1 |
View Market Depth
| Last trade - 14.21pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |